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Abstract Preimplantation factor (PIF) is secreted by viable mammalian embryos and promotes implantation and trophoblast

invasion. Whether PIF also has a direct protective or promoting effect on the developing embryo in culture is unknown. This study
examined the protective effects of synthetic PIF (sPIF) on embryos cultured with embryo toxic serum (ETS) from recurrent
pregnancy loss patients (n = 14), by morphological criteria at 72 h of culture, and determined sPIF-promoting effect on singly
cultured bovine IVF embryo development. sPIF negated the ETS-induced effect by increasing mouse blastocyst rate versus other
embryonic stages (odds ratio (OR) 2.01, 95% confidence intervals (CI) 1.14–3.55, chi-squared = 12.74, P = 0.002), increased
blastocyst rate (39.0% versus 23.7% ETS alone) and lowered embryo demise rate (11.0% versus 28.8%, OR 0.24, 95% CI 0.11–0.54),
which was not replicated by scrambled PIF or the control. sPIF added to bovine embryos for 3 days promoted development at day 7
of culture (11% versus 0%, chi-squared = 4.0, P = 0.045). In conclusion, sPIF prevented embryo demise caused by exposure to ETS and
promoted development of singly cultured bovine IVF embryos following short-term exposure. sPIF-based therapy for reducing
recurrent pregnancy loss and improving lagging cultured IVF embryo development should be explored. RBMOnline
ª 2011, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
KEYWORDS: embryo development/survival, embryo toxic serum, preimplantation factor, recurrent pregnancy loss, trophic effect
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Introduction
The viable mammalian embryo (semi-allograft) controls its
own destiny. It has been postulated that the embryo emits
specific ‘pro-pregnancy’ signals to the mother/host
throughout viable pregnancy (Barnea and Coulam, 1997).
In situ, within the uterus, these signals support implantation
(Aplin and Kimber, 2004; Paidas et al., 2010) and systemically, at the periphery, they induce and/or maintain
immune tolerance without causing deleterious immune suppression (Chaouat et al., 2010). Given pregnancy’s unique
immune milieu, it is expected that specific embryo-derived
compounds play a crucial modulating role leading to maternal recognition and tolerance of pregnancy. To orchestrate
such a ‘cross-talk’, a viable embryo must be present and will
be accepted by the mother. Whereas, a non-viable conceptus will be rejected and maternal acceptance and tolerance
for the embryo will not develop (Barnea, 2004).
In patients with recurrent pregnancy loss (RPL), many
embryos are aneuploid (non-viable) and self-eliminated
(most fail to implant) since maternal recognition of pregnancy does not initiate (Allison and Schust, 2009; Suzumori
and Sugiura-Ogasawara, 2010). Impaired maternal receptivity and failure to develop tolerance toward the embryo are
also important causes of RPL. In at least 25% of cases, the
serum of RPL patients is toxic when added directly to the
medium of cultured embryos. Assaying embryo toxicity in
the embryo toxic serum (ETS) is therefore used as a screening diagnostic tool for these patients (Fein et al., 1998;
Kaider et al., 1999; Roussev et al., 1995). However, since
specific factors that are present in ETS have remained
poorly defined to date, effective clinical countermeasures
are yet to be identified (Chávez and McIntyre, 1984; Haimovici et al., 1998; Klein, 1997; Sargent and Dokras, 1996;
Ito et al., 1996; Ornoy, 2007; Roussev et al., 1995; Thomason et al., 1995). Among several other factors, certain
auto-antibodies directly target the embryo and impair its
development (Kaider et al., 1999).
The Barnea group reported that viable mouse embryos
secrete preimplantation factor (PIF), a peptide that is present in maternal circulation and expressed by the placenta
(Barnea, 2004; Barnea et al., 1999; Roussev et al., 1996
(Barnea et al., 2007; Barnea, 2007a,b, Barnea and Sharma,
2006; Than et al., 2007). Synthetic PIF analogue (sPIF), replicating native PIF action, modulates peripheral immune
cells to create tolerance without immune suppression and
so is effective in controlling autoimmunity (Barnea, 2007b;
Weiss et al., 2011). sPIF at a concentration range present
in pregnant women (0.16–0.20 lg/ml) displays essential
multitargeted effects, regulating immunity, promoting
embryo-decidual adhesion and regulating apoptosis in cultured human decidual cells (Paidas et al., 2010). sPIF also
promotes human trophoblastic cell invasion, reflecting its
autotrophic effect on the developing placenta (Duzyj
et al., 2010). Recently it was reported that, using
anti-PIF-based monoclonal antibody enzyme-linked immunosorbent assay, PIF concentrations in cultured mouse and
bovine preimplantation embryos correlate with their progress to the blastocyst stage. Further, endogenous PIF is
also required for optimal embryo development, likely
through an autotrophic effect (Stamatkin et al., 2011).
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Because endogenous PIF plays a critical role in embryo
development, exogenous (added) sPIF also could be effective in protecting embryos against various environmental
insults prior to implantation. To examine such possibility,
two complementary in-vitro models in two different species
were studied.
First whether sPIF can reduce toxicity was tested by
adding it to mouse embryos cultured with toxic serum
derived from several RPL patients having diverse aetiologies. This mimics the maternal environment to which the
embryo is exposed prior to implantation, at the most vulnerable stage of pregnancy. Such data could help in
designing a targeted therapy that would reduce chromosomally competent RPL.
A second culture model used a bovine model, where IVF
embryos develop poorly mostly when cultured alone, since
no optimal culture methods have been thus far developed.
In contrast to humans, the currently available culture
methods in multiple species do not sustain a good embryo
development potential. Herein, this study tested whether
sPIF added in the short term can improve long-term
embryo development in culture, which is also relevant
for human IVF as a possible treatment for lagging but viable embryos.

Materials and methods
Peptide synthesis
sPIF (MVRIKPGSANKPSDD) and scrambled PIF (GRVDPSNKSMPKDIA) were obtained by solid-phase peptide synthesis
(Peptide Synthesizer, Applied Biosystems, Foster City, CA,
USA) using 9-fluorenylmethoxycarbonyl chemistry. Final
purification was conducted by reverse-phase HPLC and
identity was verified by matrix-assisted laser desorption/
ionization time-of-flight spectrometry and amino acid
analysis (Biosynthesis, Lewisville, TX, USA).

sPIF effect on mouse embryos cultured with ETS
The study was approved by the CARI Research Institute, Chicago, IL, USA. A total of 30 archived frozen serum samples
from patients with RPL of various aetiologies were studied.
Fourteen serum samples which were previously found to be
toxic for cultured mouse embryos (ETS) and 16 sera which
were non-toxic, were studied using established criteria
(Kaider et al., 1999; Roussev et al., 1995). Briefly,
2-cell-stage embryos were collected from superovulated
mated CB6F1/J mice. Removed oviducts were dissected
under microscope and embryos were removed into modified
human tubal fluid culture medium (cat. 2001 InVitroCare,
Frederick, MD, USA). Embryos were cultured in Nunc in
500 ll culture medium under mineral oil by incubating at
37C with 5% CO2 for 3 days maintaining pH 7.2 throughout
the experiment. Embryos were cultured with 0–15% ETS
or non-toxic-serum sPIF (0.043–3.12 lg/ml) adjusting the
total culture volume with 2% bovine serum albumin in all
cases to 500 ll. Results were compared with scrambled
PIF (the same composition as PIF but with the amino acids
in a random order) and tested in parallel or medium alone,
both serving as controls. At the end of the culture period
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at 72 h, embryos’ developmental stages were recorded
using established morphological criteria by microscopy
(Stamatkin et al., 2011). Embryos were categorized as blastocysts, pre-blastocysts, morula, number of cells, 6–8, 2–4
or atretic embryos, and evaluated by two different observers (CWS, RGR).

IVF procedure to retrieve bovine oocytes
At the Louisiana State University Embryo Biotechnology Laboratory, IVF was performed on bovine oocytes obtained
from a commercial source (Ovitra, TX, USA). Oocytes
arrived in a climate-controlled container via Fedex
approximately 24 h following their collection. A standard
bovine IVF laboratory procedure was performed on groups
of 10 oocytes in 40 ll droplets of fertilization medium
(IVF-Tyrode’s albumin lactate pyruvate). Briefly, 2 ll heparin (2 lg/ml), 2 ll penicillamine, hypotaurine and epinephrine and 2 ll spermatozoa were added to each fertilization
droplet with the meiosis-II oocytes. This made the total
medium volume 46 ll. Frozen–thawed spermatozoa from
a fertile Holstein bull was used in these experiments
(Purpera et al., 2009) The IVF interval was 18 h, incubated
in a humidified atmosphere of 5% CO2 in air at 39C. Following fertilization, the presumptive zygotes were removed
from the fertilization droplets and treated with hyaluronidase (1 mg/ml) to remove the cumulus cells. The embryos
were then washed in HEPES-Tyrode’s albumin lactate
pyruvate medium and transferred to CR1aa culture medium
(Rosenkrans and First, 1994). A single embryo from the
group of IVF-derived embryos was then placed into a fresh
40 ll droplet of CR1aa at 39C in a humidified atmosphere
of 5% CO2 in air. On day 3 of culture, individual embryos
were transferred to a new 40 ll droplet of CR1aa and
incubated under the same conditions until day 7 of culture.
At the end of the experiment embryos were assigned a quality grade (1 = good, 3 = poor) and evaluated for morphological development (2-cell to blastocyst).

Addition of sPIF to IVF-derived bovine embryos
during in-vitro culture
There are no effective culture methods to achieve a high
rate of blastocyst formation in the bovine species following
IVF. To examine whether PIF could improve that rate, IVF
was performed on bovine meiosis-II oocytes (n = 100). The
study used 0.16 lg/ml sPIF since this is the concentration
of the peptide previously found effective to modulate
decidual function and trophoblast invasion (Duzyj et al.,
2010; Paidas et al., 2010). Following the IVF procedure,
sperm-exposed oocytes (n = 74) were randomly allotted
to two treatment groups. Treatment A included culturing
zygotes in 40 ll droplets of CR1aa with 100 nM (0.16 lg/ml)
exogenous sPIF (n = 37) added immediately prior to culture. Treatment B included culturing zygotes without the
addition of sPIF (n = 37) and served as control. On day 3
of culture, developing embryos from both groups were
individually transferred to fresh 40 ll droplets of CR1aa
and cultured to day 7. Morphological development of the
embryos was compared between the two groups at culture
days 3 and 7.
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Statistical analysis
Data were analysed using a multigroup chi-squared analysis
determining the odds ratio (OR) and 95% confidence interval
for ETS experiments. In other studies a multigroup
chi-squared analysis was carried out using Analyse-it for
Microsoft Excel. P < 0.05 was considered to be significantly
different in these studies.

Results
Serum of certain patients with RPL were toxic for embryos.
Initially the toxicity of previously frozen archived ETS samples was confirmed (Table 1). It demonstrated that at 10%
concentration, practically all embryos became atretic,
whereas at lower concentrations, 5% ETS and below, some
embryos did survive following exposure. This documented
that the ETS effect was dose-dependent and that 5% ETS
was suitable to test the sPIF-protective effect.
sPIF protected against ETS derived from patients with
RPL. This study tested whether sPIF could block ETS-induced
adverse effects on embryos when added into the culture
medium. Consequently, a checkerboard-type analysis was
carried out to compare the effect of different ETS concentrations added to cultured mouse embryos with and without
different sPIF concentrations (Table 2). As expected, the
high-concentration (15%) ETS led to the demise of all
embryos. At 5% ETS, the effect was still significant, although
not all embryos became atretic (P < 0.0001). Addition of
sPIF (0.78 lg/ml) to this culture medium was effective in
negating toxicity, as compared with 5% ETS alone
(chi-squared P = 0.02). The higher sPIF concentrations
exposed to 5% ETS were less effective. The data also demonstrated that 3.12–0.78 lg/ml sPIF tested alone was not
toxic and that the number of blastocysts that developed
was similar to the medium-only control.
Lower sPIF concentrations were less effective in negating
ETS. Lower sPIF doses were also tested to confirm that the
0.78 lg/ml dose was the most effective. Table 3 shows an
independent experiment, where the 0.124 lg/ml dose was
tested using ETS from 10% to 1%. Data showed that the sPIF
effect was borderline (not statistically significant) at 10%
ETS. However, it was effective in negating toxicity at 5%
ETS (chi-squared P = 0.03). When the protective effect of
sPIF was compared against 5% ETS, obtained at 0.124 lg/ml,

Table 1

Embryo toxic serum is toxic for embryos.

Embryo

Blastocyst
Pre-blastocyst
Morula
6–8 Cells
2–4 Cells
Atretic

Embryo toxic serum (%)
10

5

2.50

1

0

0
0
0
0
0
10

0
0
0
0
1
8

5
2
3
0
0
0

4
3
2
1
0
0

23
5
2
0
0
0

Values are n. Mouse embryos (n = 9–30/group) were cultured in
presence of various concentrations of embryo toxic serum for 72 h.
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Table 2 Checkerboard analysis: serum of a patient with
recurrent pregnancy loss is toxic to mouse embryos and
synthetic preimplantation factor acts as a rescue factor.
Embryo

Synthetic preimplantation factor
3.12
lg/ml

15% ETS
Blastocyst
Pre-blastocyst
Morula
6–8 Cells
2–4 Cells
Atretic
5% ETS
Blastocyst
Pre-blastocyst
Morula
6–8 Cells
2–4 Cells
Atretic
1% ETS
Blastocyst
Pre-blastocyst
Morula
6–8 Cells
2–4 Cells
Atretic
Control
Blastocyst
Pre-blastocyst
Morula
6–8 Cells
2–4 Cells
Atretic

1.56
lg/ml

0.78
lg/ml

Table 3 Lower synthetic preimplantation factor (sPIF) concentrations are less effective in negating embryo toxic serum
(ETS) toxicity.
Embryo

Control

0.124 lg sPIF

P-value

0
0
0
0
0
10

0
1
2
0
0
8

NS
–
–
–
–
–

0
0
0
0
1
8

1
1
2
0
2
4

0.03a
–
–
–
–
–

5
2
3
0
0
0

6
2
2
0
0
0

NS
–
–
–
–
–

4
3
2
1
0
0

7
2
1
0
0
0

NS
–
–
–
–
–

Control

0
0
0
0
2
8

0
0
0
0
1
9

0
0
0
0
1
9

0
0
0
0
2
8

1
2
3
4
0
0

2
1
4
3
0
0

6a
0
3
1
0
0

1
0
4
1
0
0

8
2
0
0
0
0

9
1
0
0
0
0

9
1
0
0
0
0

10
0
0
0
0
0

8
2
0
0
0
0

10
0
0
0
0
0

8
2
0
0
0
0

10
0
0
0
0
0

Various concentrations of embryo toxic serum (ETS) were added to
mouse embryo cultures (n = 10/group) in presence of synthetic
preimplantation factor (sPIF) at different concentrations. 5% ETS
and 0.78 lg/ml sPIF were chosen to test the peptide’s protective
effects.
a
Chi-squared = 5.5, P < 0.02.

with even lower doses which were tested in parallel
(0.024 lg/ml and 0.0043 lg/ml, the lowest dose tested),
no protection against embryo toxicity was observed and
only 0/10 and 1/10 embryos survived, respectively. Thus
the sPIF effect was bell-shaped and was effective at a narrow range of concentrations. Although the lower sPIF dose
(0.124 lg/ml) was effective, it was not as pronounced as
with the 0.78 lg/ml dose. Therefore, the protective effects
of sPIF were further examined using a fixed maximally
effective dose of the peptide combined with fixed 5% ETS
serum derived from different patients.
sPIF rescued embryos cultured in ETS serum derived from
different RPL patients. To further validate the initially
observed sPIF-induced embryo protective effects against
toxicity ETS sera, six independent studies each testing a different patient serum were carried out to confirm the observations in a larger number of embryos. Addition of sPIF
(0.78 lg/ml) to cultured embryos (n = 113/group) negated

10% ETS
Blastocyst
Pre-blastocyst
Morula
6–8 Cells
2–4 Cells
Atretic
5% ETS
Blastocyst
Pre-blastocyst
Morula
6–8 Cells
2–4 Cells
Atretic
2.5% ETS
Blastocyst
Pre-blastocyst
Morula
6–8 Cells
2–4 Cells
Atretic
1% ETS
Blastocyst
Pre-blastocyst
Morula
6–8 Cells
2–4 Cells
Atretic

Various concentrations of ETS were added to mouse embryo cultures (n = 9–10/group). In the presence of 0.124 lg/ml sPIF, the 5%
ETS-induced toxicity was negated. However, the degree of protection was lower than observed with the higher sPIF concentration.
NS = not statistically significant.
a
Chi-squared test.

5% ETS-induced toxicity by acting as a ‘rescue factor’. Specifically, sPIF increased the blastocyst rate (39.0%) as compared with ETS alone (23.7%) while reducing the atretic
embryo rate (11.0% versus 28.8%, control, respectively;
Fig. 1). Table 4 shows the number of blastocysts and atretic
embryos following treatment with sPIF in the combined
experiments. It demonstrates that sPIF negated the ETS
effect by increasing mouse blastocyst percentage as compared with all other developmental stages including atretic
embryos (chi-squared = 12.74, P = 0.002). Table 5 shows the
significant OR using the different models of analysis. Thus
sPIF exposure doubled the odds of an embryo developing
to the blastocyst stage compared with ETS alone. On the
other hand, sPIF reduced three-fold the likelihood of an
embryo becoming atretic as compared with ETS alone.
Therefore sPIF protection against a maternally induced
toxic environment was dual, increasing blastocysts while
decreasing atretic embryos.
The protective effect of sPIF was specific and was not
replicated by the control peptide. In contrast to sPIF,

PIF has embryo protective effects
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%Embryo Development Stage

100%
90%
80%
70%
60%
50%

PIF +

*

PIF –

40%
30%
20%

*

10%
0%

Blastocyst

PreMorula
blastocyst

6–8 cell

2–4 cell

Atretic

Fig. 1 Synthetic preimplantation factor (sPIF) protects against toxicity of embryo toxic serum (ETS). Mouse embryos were cultured
with 5% ETS and 0.78 lg/ml sPIF, which increased blastocyst formation rate while reducing significantly atretic embryos as
compared with ETS-only treated embryos (chi-squared = 12.74, P < 0.002). Table 1 details the statistical analysis of the six
independent experiments.

Table 4 Synthetic preimplantation factor (sPIF) protects
against embryo toxic serum-induced toxicity.
Treatment

Blastocyst

Other

Atretic

Total

sPIF
No sPIF
Total

45
28
73

55
52
107

13
33
46

113
113
226

Values are n. Other = pre-blastocyst, morula, 6–8 cells and 2–4
cells.
Chi-squared = 12.74, P = 0.002.

scrambled PIF (3.12–0.78 lg/ml) added to embryos
(n = 14–40/group) did not protect against ETS-induced toxicity, demonstrating that the sPIF effect was specific (data
not shown).
High-dose sPIF did not affect embryos cultured under
optimal conditions. The initial study (Table 1) showed that
when sPIF alone was tested at a high 3.12 lg/ml concentration, cultured embryo development was similar to medium
control. The study was repeated again (Fig. 2) and showed
that the effects of sPIF and media-alone treatment were
similar (84% versus 77% blastocyst rate). Thus high-dose sPIF
appeared to be safe as it did not interfere with normal
embryo development.
sPIF promoted cultured IVF-derived bovine embryo
development. To demonstrate sPIF’s ability to enable

Table 5

Discussion
Preimplantation factor (PIF) secreted by viable embryos
reaches maternal circulation where it plays a critical role
to create maternal tolerance and promote embryo implantation, starting post fertilization (Duzyj et al., 2010; Paidas
et al., 2010). Endogenous PIF is further required for embryo
development acting through possible autocrine mechanisms
having a self-sustaining role (Stamatkin et al., 2011). Herein
this study reports that sPIF added to mouse embryo cultures
acts as a rescue factor negating ETS-induced toxicity by
increasing blastocysts and reducing atretic embryos. Thus
sPIF-based therapy may have a role in reducing recurrent

Odds ratio (OR) analysis of synthetic preimplantation factor (sPIF) effect on embryo morphology.

OR ratio
calculation
sPIF
No sPIF

embryos to overcome the frequently encountered developmental arrest when cultured in single cultures, a second
model was used. Single bovine IVF-derived zygotes were cultured with 0.16 lg/ml sPIF or medium alone for 3 days
(n = 37/group), followed by change of culture media without added sPIF and observation until day 7 of culture. After
3 days of culture, no differences between sPIF-treated
zygotes versus untreated controls were found (83% versus
75% cleavage rate). Table 6 shows that after 7 days 17%
of sPIF-treated zygotes progressed and reached >16 cells
versus none reaching such an advanced stage of development in the control (degrees of freedom = 4,
chi-squared = 4.0, P = 0.045). Thus short-term sPIF administration improved embryo development and the peptide’s
effect persisted even post exposure.

Model 1: blastocyst versus all other
embryosa

Model 2: atretic versus all other
embryosa

Model 3: blastocyst versus atretic
embryosb

2.01 (1.14–3.55)
Reference

0.32 (0.15–0.64)
Reference

0.24 (0.11–0.54)
Reference

Values are OR (95% confidence interval).
a
n = 226 embryos.
b
Subset of n = 119 embryos with either blastocyst or atretic outcome.

%Embryo Developmental Stage
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100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

sPIF
Control

Control
sPIF

Bl t
Blastocyst
t

E
Early
l St
Stage

Fig. 2 High-dose exogenous synthetic preimplantation factor
(sPIF) does not affect embryos cultured under optimal conditions. Embryos were cultured with 3.12 lg/ml sPIF up to the
blastocyst stage. Blastocyst rate of formation was slightly
better than controls. Results are composite of two independent
experiments.

Table 6 Short-term synthetic preimplantation
factor (sPIF) addition promotes singly cultured
bovine embryos development in the long term.
Embryo
Day 3
NC
2 Cells
3 Cells
4 Cells
5 Cells
6 Cells
8 Cells
16 Cells
% Cleavage
Day 7
Degenerate
ND
5 Cells
8 Cells
16 Cells
32 Cells
Morula
Blastocyst
% Cleavage

No sPIF

sPIF

9 (24)
4 (11)
3 (8)
9 (24)
0 (0)
6 (16)
6 (16)
0 (0)
76

6 (16)
8 (22)
3 (8)
9 (24)
1 (3)
3 (8)
6 (16)
1 (3)
84

16 (57)
9 (32)
1 (3)
1 (3)
1 (3)
0 (0)
0 (0)
0 (0)
11

17 (57)
8 (27)
0 (0)
1 (3)
0 (0)
1 (3)
2 (7)
1 (3)
17

Singly cultured bovine embryos were exposed to
0.16 lg/ml sPIF for 3 days. Subsequently the media
was changed and embryos were cultured for an
additional 4 days. After 3 days there was already a
slight increase in the cleavage rate. However, at day
7 of culture none of the control embryos progressed
beyond the 16-cell stage as compared with the sPIFtreated embryos, chi-squared = 4.0 P = 0.045.

miscarriage rates in patients with ETS. sPIF also promotes
suboptimally cultured bovine embryo development and
may aid in lagging embryos’ progress to blastocyst stage.
RPL remains a serious condition with few established
effective targeted therapies. Beyond embryonic aneuploidy
which causes up to 60% of losses, the rest may be amenable

for therapy. Despite intense efforts, no uniform and specific
therapies have been developed to treat RPL. The aim is to
improve maternal environment, including the immune
milieu, and make it receptive for the embryo. Studies have
demonstrated that PIF has such an effect on the decidua,
as well as promoting trophoblast invasiveness (Duzyj et al.,
2010; Paidas et al., 2010). There is evidence that circulating
toxins and antibodies are present in the serum of some RPL
patients which may cause the demise of exposed embryos.
However, targeted interventions to negate such toxicity to
improve patient outcome have not been addressed previously. Using sPIF as a protective agent in this embryo culture
model was intended to specifically examine a possible therapeutic approach. Using total ETS provided a suitable model
to determine an overall adverse maternal environment that
the embryo might encounter post fertilization and prior to
implantation, thereby mimicking the in-vivo scenario.
The embryo at the peri-implantation phase is most vulnerable to exposure to an adverse (toxic) maternal environment (Kaider et al., 1999). sPIF added to mouse embryos
cultured in groups was successful in negating ETS-induced
toxicity derived from non-pregnant RPL patients. Such data
on PIF-induced embryo protection create a strong link
between embryo self-preservation and its ability to negate
maternal hostility successfully. sPIF both increased blastocyst formation and reduced atretic embryo rates when
exposed to 5% ETS. The protective effect was confirmed
by testing several patients expected to have diverse RPL
aetiologies because of various toxins and antibodies (Kaider
et al., 1999). As sPIF protected both ends of the spectrum of
embryo development, it could counteract the embryo-toxic
agents that cause a delay in development or lead to demise.
As far as is known, this is the first report that exogenous sPIF
negates ETS-induced effects and acts as an embryo rescue
factor.
Such embryo-protective effects were not obtained by
testing other known factors including transforming growth
factor a, gonadotrophin-releasing hormone I analogue, insulin growth factors, acrogranin, epidermal growth factor,
embryotrophic factor 3 and granulocyte-macrophage colony-stimulating factor (Block and Hansen, 2007; Brinson,
2000; Diaz-Cueto et al., 2000; Jousan et al., 2008; Kawamura
et al., 2005, 2007; Sjoblom et al., 2002; Wei et al., 2001;
Xu et al., 2004). The specificity of the protective action of
sPIF was documented by using scrambled PIF (the same
amino acids as sPIF but in a random order) as a control,
which had no discernible protective effect. This protection is in line with data demonstrating that fluorescein
isothiocyanate (FITC) PIF is taken up by the bovine blastocyst thus aiding in its self-preservation. In contrast, FITC
scrambled PIF failed to bind demonstrating specificity
(Stamatkin et al., 2011). The minimal protective effect of
sPIF at high concentrations might be due to down-regulation
of putative embryo binding site(s). As sPIF reversed ETS
effects from several patients, very likely of different
aetiologies, the current study suggests that sPIF may be a
targeted therapy for treating RPL patients, especially those
with ETS activity. Evidencing PIF’s potential safety, this
study demonstrates that high-dose sPIF added to mouse
embryos cultured under optimal conditions is safe, reflecting exogenous sPIF effectiveness directly, acting only
according to need.

PIF has embryo protective effects
To demonstrate the sPIF-promoting effect on cultured
IVF embryos, this study used a single bovine-embryo model
as it compares well with the single human IVF embryo
model. sPIF improved bovine IVF embryo development and
thereby could aid in improving lagging embryo progress to
blastocysts. The bovine embryo model is the closest to
human embryos because of similar expression of OCT4 (Berg
et al., 2011).
In singly cultured bovine IVF embryos, in contrast to
human, lack of supportive cross-talk greatly impairs embryo
development. The poor progress is also caused by the
ill-defined culture conditions available for bovine embryos.
In reality, in this study, only a few of several hundred embryos
cultured reached the blastocyst stage without treatment at
day 7 of culture. Presence of detectable PIF concentrations
in the medium of individually cultured bovine embryos was
associated with progress up to the blastocyst stage (Stamatkin et al., 2011). A low sPIF concentration added to these
embryos in the short term improved their long-term development. Possibly, sPIF-induced zygote activation triggered an
endogenous PIF production as well, leading to the continued
autocrine-trophic effect which also lasted after removing
sPIF from the culture medium. These trophic effects of sPIF
are particularly relevant in a hot climate such as Louisiana
where the heat-stressed bovine oocytes were collected for
the current study (Flamenbaum and Galon, 2010). Fertilizing
all bovine oocytes using the same sperm donor assured uniformity of the fertilization process and avoided a possible
embryo selection bias. Culturing bovine and other species’
embryos in groups improves development, suggesting the
presence of embryo cross-talk (Contramaestre et al., 2008;
Gopichandran and Leese, 2006; Stokes et al., 2005; Teruel
et al., 2005; Guérin and Ménézo, 2010). sPIF added to single
bovine IVF embryos produced a similar promoting effect.
Hence, sPIF could optimize IVF embryos outcome by promoting those that were viable but delayed because of suboptimal
culture conditions. In human IVF, sPIF could also improve the
development of lagging embryos from poor responders in a
safe and targeted manner.
This study has certain limitations. Although implied, the
direct translation of sPIF-based therapy for treating RPL
patients has to be confirmed in a clinical setting. sPIF has
unique immune-modulatory properties and is effective in
preclinical models (Barnea, 2007a,b; Weiss et al., 2011).
Clinical trials for treating non-pregnant patients with
immune disorders are planned shortly, following ongoing
FDA-directed toxicology studies (Reuven Or, Clinical Trials.gov). Also, observations made on bovine embryos may
not be directly translatable to the human IVF setting
because of species differences.
The strength of the study is the checkerboard testing of
sPIF and ETS combinations, defining best testing conditions,
and multiple independent experiments from several
patients analysed by rigorous statistical analysis. The use
of scrambled PIF as a negative control demonstrated sPIF’s
specificity. The use of single-embryo IVF cultures to test
sPIF under harsh conditions documented its promoting properties, especially since sPIF had no effect under optimal culture conditions.
sPIF protected against embryo toxicity induced by serum
derived from RPL patients, increasing blastocysts and
reducing atretic embryos irrespective of the putative
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offending agent(s) present in ETS. Further, sPIF promoted
bovine embryo development by overcoming the developmental arrest present in this species. The sPIF effect was
direct and defined on the embryo. Therefore, sPIF therapy
may benefit patients experiencing RPL and sPIF added to
culture could promote suboptimal embryo development.
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